Preview

Современная ревматология

Расширенный поиск

Системная красная волчанка и в и тамин D

https://doi.org/10.14412/1996-7012-2015-2-57-65

Полный текст:

Аннотация

В обзоре представлены данные литературы о частоте гиповитаминоза D при системной красной волчанке (СКВ), проанализирована ассоциация клинико-лабораторных параметров заболевания и уровня витамина D, рассмотрены возможности терапевтического применения его метаболитов. Дефицит витамина D является весьма распространенным патологическим состоянием, создающим предпосылки для развития широкого круга болезней. Низкий сывороточный уровень витамина D может быть связан с недостаточной солнечной экспозицией, генетической предрасположенностью (полиморфизм рецепторов витамина D) и алиментарными факторами, а также сопутствовать аутоиммунным заболеваниям. Выявленные иммуномодуляторные свойства витамина D представляют интерес с точки зрения возможного участия данного гормона в патогенезе аутоиммунных заболеваний. Ряд исследователей предлагает рассматривать витамин D как модифицируемый фактор окружающей среды, участвующий в развитии аутоиммунных заболеваний. Имеются данные о связи низкого сывороточного уровня 25(ОН)D c риском развития, активностью, тяжестью и прогнозом некоторых ревматических заболеваний (в первую очередь ревматоидного артрита и СКВ), что требует дальнейшего изучения. Антирезорбтивное, противовоспалительное и иммуномодулирующее действие метаболитов витамина D обосновывает целесообразность их применения при хронических воспалительных заболеваниях в комбинации с традиционными базисными средствами.

Об авторе

Н. Г. Клюквина
Институт профессионального образования ГБОУ ВПО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России, Москва, Россия 119048, Москва, ул. Трубецкая, 8, стр. 2
Россия


Литература

1. Gatenby P, Lucas R, Swaminathan A. Vitamin D deficiency and risk for rheumatic diseases. Curr Opin Rheumatol. 2013 Mar;25(2):184–91. doi: 10.1097/BOR.0b013e32835cfc16.

2. Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266–81.

3. Cutolo M. Vitamin D and autoimmune rheumatis diseases. Rheumatology (Oxford). 2009 Mar;48(3):210–2. doi: 10.1093/rheumatology/ken394. Epub 2008 Oct 17.

4. Holick MF, Garabedian M. Vitamin D: photobiology, metabolism, mechanism of action and clinical applications. In: Favus MJ, et al, editors. Primer on the metabolic bone disease and disorders of mineral metabolism. 6th ed. Washington, DC: American Society for Bone and Mineral Research; 2006. P. 129–137.

5. DeLuca HF. Overview of general physiologic features and functions of vitamin. Am J Clin Nutr. 2004 Dec;80(6 Suppl): 1689S–96S.

6. Торопцова НВ, Аникин СГ. Витамин D и ревматоидный артрит: что мы знаем сегодня? Научно-практическая ревматология. 2011;(3):46–51. [Toroptsova NV, Anikin SG. Vitamin D and rheumatoid arthritis: What do we know today? Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2011;(3):46–51. (In Russ.)]. DOI: ttp://dx.doi.org/10.14412/1995-4484- 2011-573

7. Ibrahim MH, Bakheet MS, Abdel-Safer KA, Shakoor MA. Relationship between vitamin D and disease activity in some rheumatic diseases. Int J Nutr Metab 2013;5(7):114–27. DOI: 10.5897/IJNAM2013.0153

8. Насонов ЕЛ. Кальций и витамин D: роль в профилактике и лечении остеопороза и других заболеваний человека. Consilium medicum. 1999; 1(5):212–4. [Nasonov EL. Calcium and vitamin D: role in the prevention and treatment of osteoporosis and other diseases. Consilium medicum. 1999; 1(5):212–4. (In Russ.)].

9. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005 Aug;26(5):662–87. Epub 2005 Mar 29.

10. Mathieu C, Adorini L. The coming of age of 1,25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends Mol Med. 2002 Apr;8(4):174–9.

11. Dawson-Hughes B, Heaney RP, Holick MF, et al. Estimates of optimal vitamin D status. Osteoporos Int. 2005 Jul;16(7):713–6. Epub 2005 Mar 18.

12. Holick MF. Vitamin D deficiency. N Engl J Med. 2007 Jul 19;357(3):266–81.

13. Gordon CM, DePeter KC, Feldman HA, et al. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med. 2004 Jun;158(6):531–7.

14. Melamed ML, Michos ED, Post W, Astor B. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med. 2008 Aug 11;168(15):1629–37. doi: 10.1001/archinte.168.15.1629.

15. Cutolo M, Otsa K. Review: vitamin D, immunity amd lupus. Lupus. 2008 Jan;17(1):6–10.

16. Nair R, Maseeh A. Vitamin D: the «sunshine » vitamin. J Pharmacol Pharmacother. 2012 Apr;3(2):118–26. doi: 10.4103/0976-500X.95506.

17. Autier P, Gandini S. Vitamin D supplementation and total mortality: A meta-analysis of randomized controlled trials. Arch Intern Med. 2007 Sep 10;167(16):1730–7.

18. Muller K, Kriegbaum NJ, Baslund B, et al. Vitamin D3 metabolism in patients with heumatic diseases: low serum levels of 25-hydroxyvitamin D3 in patients with systemic lupus erythematosus. Clin Rheumatol. 1995 Jul;14(4):397–400.

19. Bikle DD. What is new in vitamin D: 2006–2007. Curr Opin Rheumatol. 2007 Jul;19(4):383–8.

20. Kamen D, Aranow C. Vitamin D in systemic lupus erythematosus. Curr Opin Rheumatol. 2008 Sep;20(5):532–7. doi: 10.1097/BOR.0b013e32830a991b.

21. Kamen DL, Cooper GS, Bouali H, et al. Vitamin D deficiency in systemic lupus rythematosus. Autoimmun Rev. 2006 Feb;5(2):114–7. Epub 2005 Jun 21.

22. Mok СС, Birmingham DJ, Ho LY, et al. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus. 2012 Jan;21(1):36–42. doi: 10.1177/0961203311422094. Epub 2011 Oct 12.

23. Carvalho JF, Blank M, Kiss E, et al. Antivitamin D, vitamin D in SLE: preliminary results. Ann N Y Acad Sci. 2007 Aug;1109:550–7.

24. Le Goaziou MF, Contardo G, Dupraz C, et al. Risk factors for vitamin D deficiency in women aged 20–50 years consulting in general practice: a crosssectional study. Eur J Gen Pract. 2011 Sep;17(3):146–52. doi: 10.3109/13814788.2011.560663. Epub 2011 Feb 25.

25. Ben-Zvi I, Aranow C, Mackay M, et al. The impact of vitamin D on Dendritic cell function in patients with systemic lupus erythematosus. PLoS One. 2010 Feb 16;5(2): e9193. doi: 10.1371/journal.pone.0009193.

26. Amital H, Szekanecz Z, Szü cs G, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D? Ann Rheum Dis. 2010 Jun;69(6):1155–7. doi: 10.1136/ard.2009.120329. Epub 2010 May 3.

27. Cutillas-Marco E, Morales-Suarez-Varela M, Marquina-Vila A, Grant W. Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region. Lupus. 2010 Jun;19(7):810–4. doi: 10.1177/09612033 09360807. Epub 2010 Mar 19.

28. Kim HA, Sung JM, Jeon JY, et al. Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus. Rheumatol Int. 2011 Sep;31(9):1189–94. doi: 10.1007/s00296-010-1442-1. Epub 2010 Mar 30.

29. Szodoray P, Tarr T, Bazso A, et al. The immunopathological role of vitamin D in patients with SLE: data from a single centre registry in Hungary. Scand J Rheumatol. 2011 Mar;40(2):122–6. doi: 10.3109/03009742. 2010.507220. Epub 2010 Oct 26.

30. Toloza SM, Cole DE, Gladman DD, et al. Vitamin D insufficiency in a large female SLE cohort. Lupus. 2010 Jan;19(1):13–9. doi: 10.1177/0961203309345775. Epub 2009 Nov 6.

31. Cusack C, Danby C, Fallon JC, et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed. 2008 Oct;24(5):260–7. doi: 10.1111/j.1600- 0781.2008.00373.x.

32. Kamen DL, Cooper GS, Bouali H, et al. Vitamin D deficiency in systemic lupus rythematosus. Autoimmun Rev. 2006 Feb;5(2):114–7. Epub 2005 Jun 21.

33. Ruiz-Irastorza G, Egutide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford). 2008 Jun;47(6):920–3. doi: 10.1093/rheumatology/ ken121. Epub 2008 Apr 14.

34. Ruiz-Irastorza G, Gordo S, Olivares N, et al. Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity and damage. Arthritis Care Res (Hoboken). 2010 Aug;62(8):1160–5. doi: 10.1002/acr.20186.

35. Wu PW, Rhew EY, Dyer AR, et al. 25-Hydroxyvitamin D and cardiovascular risk factors in women with systemic lupus erythematosus. Arthritis Rheum. 2009 Oct 15;61(10):1387–95. doi: 10.1002/art.24785.

36. Reynolds JA, Hague S, Berry JL, et al. 25-hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus. Rheumatology (Oxford). 2012 Mar;51(3):544–51. doi: 10.1093/rheumatology/ker352. Epub 2011 Nov 24.

37. Mok CC, Birmingham DJ, Leung HW, et al. Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. Rheumatology (Oxford). 2012 Apr;51(4):644–52. doi: 10.1093/rheumatology/ker212. Epub 2011 Jun 29.

38. Birmingham DJ, Hebert LA, Song H, et al. Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus. 2012Jul;21(8):855–64. doi: 10.1177/0961203 312439640. Epub 2012 Mar 20.

39. Mandal M, Tripathy R, Panda AK, et al. Vitamin D levels in Indian systemic lupus erythematosus patients: association with disease activity index and interferon alpha. Arthritis Res Ther. 2014 Feb 10;16(1):R49. doi: 10.1186/ar4479.

40. O’Regan S, Chesney RW, Hamstra A, et al. Reduced serum 1,25-(OH)2 vitamin D3 levels in prednisone-treated adolescents with systemic lupus erythematosus. Acta Paediatr Scand. 1979 Jan;68(1):109–11.

41. Husiman AM, White KP, Algra A, et al. Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol. 2001 Nov;28(11):2535–9.

42. Broder AR, Tobin JN, Putterman C. Disease-specific definitions of vitamin D deficiency need to be established in autoimmune and non-autoimmune chronic diseases: a retrospective comparison of three chronic diseases. Arthritis Res Ther. 2010;12(5):R191. doi: 10.1186/ar3161. Epub 2010 Oct 14.

43. Thudi A, Yin S, Wandstrat AE, et al. Vitamin D levels and disease status in Texas patients with systemic lupus erythematosus. Am J Med Sci. 2008 Feb;335(2):99–104. doi: 10.1097/MAJ.0b013e318134eeb6.

44. Reichel H, Koeffler HP, Tobler A, Norman AW. 1 alpha,25-dihydroxyvitamin D3 inhibits gamma-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA. 1987 May;84(10):3385–9.

45. Griffin MD, Lutz WH, Phan VA, et al. Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun. 2000 Apr 21;270(3):701–8.

46. Dobnig H, Pilz S, Scharnagl H, et al. Independent association of low serum 25- hydroxyvitamin D and 1,25-dihydroxyvitamin D Levels with all-cause and cardiovascular mortality. Arch Intern Med. 2008 Jun 23;168(12):1340–9. doi: 10.1001/archinte. 168.12.1340.

47. Scragg R, Jackson R, Holdaway IM, et al. Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol. 1990 Sep;19(3):559–63.

48. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008 Jan 29;117(4):503–11. doi: 10.1161/CIRCULATIONAHA. 107.706127. Epub 2008 Jan 7.

49. Jablonski KL, Chonchol M, Pierce GL, et al. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension. 2011 Jan;57(1): 63–9. doi: 10.1161/HYPERTENSIONAHA. 110.160929. Epub 2010 Nov 29.

50. Pilz S, Henry R, Snijder M, et al. 25-Hydroxyvitamin D is not associated with carotid intima-media thickness in older men and women. Calcif Tissue Int. 2009 May;84(5):423–4. doi: 10.1007/s00223-009-9238-6. Epub 2009 Mar 24.

51. Reis JP, von Muhlen D, Michos ED, et al. Serum vitamin D, parathyroid hormone levels, and carotid atherosclerosis. Atherosclerosis. 2009 Dec;207(2):585–90. doi: 10.1016/j.atherosclerosis.2009.05.030. Epub 2009 Jun 6.

52. Tarcin O, Yavuz DG, Ozben B, et al. Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab. 2009 Oct;94(10):4023–30. doi: 10.1210/jc.2008–1212. Epub 2009 Jul 7.

53. Watson KE, Abrolat ML, Malone LL, et al. Active serum vitamin D levels are inversely correlated with coronary calcification. Circulation. 1997 Sep 16;96(6):1755–60.

54. Bruce IN, Urowitz MB, Gladman DD, et al. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum. 2003 Nov;48(11):3159–67.

55. Esdaile JM, Abrahamowicz M, Grodzicky T, et al. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum. 2001 Oct;44(10):2331–7.

56. Angel K, Provan SA, Gulseth HL, et al. Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study. Hypertension. 2010 Feb;55(2):333–8. doi: 10.1161/HYPERTENSIONHA.109.143982. Epub 2009 Dec 28.

57. Vlachopoulos C, Aznaouridis K, tefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol. 2010 Mar 30;55(13): 1318–27. doi: 10.1016/j.jacc.2009.10.061.

58. Lertratanakul A, Wu P, Dyer A, et al. 25-hydroxyvitamin D and cardiovascular disease in patients with systemic lupus erythematosus: data from a large international inception cohort. Arthritis Care Res (Hoboken). 2014 Aug;66(8):1167–76. doi: 10.1002/acr.22291.

59. Luong K, Nguyen LT. The beneficial role of vitamin D in systemic lupus erythematosus (SLE). Clin Rheumatol. 2012 Oct;31(10):1423–35. doi: 10.1007/s10067- 012-2033-1. Epub 2012 Jul 17.

60. Alarcon GS, Friedman AW, Straaton KV, et al. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus. 1999;8(3):197–209.

61. Birmingham DJ, Hebert LA, Song H, et al. Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans. Lupus. 2012 Jul;21(8):855–64. doi: 10.1177/0961203312 439640. Epub 2012 Mar 20.

62. Vijay J, Kapil U. Vitamin D deficiency and its health consequences – a review. Indian J Community Health. 2012;24:232–236.

63. Malaviya AN, Singh RR, Singh YN, et al. Prevalence of systemic lupus erythematosus in India. Lupus. 1993 Apr;2(2):115–8.

64. Kumar A, Malaviya AN, Singh RR, et al. Survival in patients with systemic lupus rythematosus in India. Rheumatol Int. 1992;12(3):107–9.

65. Murali R, Jeyaseelan L, Rajaratnam S, et al. Systemic lupus erythematosus in Indian patients: prognosis, survival and life expectancy. Natl Med J India. 1997 Jul-Aug;10(4):159–64.

66. Munoz LE, Schiller M, Zhao Y, et al. Do low vitamin D levels cause problems of waste removal in patients with SLE? Rheumatology (Oxford). 2012 Apr;51(4):585–7. doi: 0.1093/rheumatology/ ker334. Epub 2011 Oct 27.

67. Carrillo-Vico A, Reiter RJ, Lardone PJ, et al. The modulatory role of melatonin on immune responsiveness. Curr Opin Investig Drugs. 2006 May;7(5):423–31.

68. Ozaki Y, Namura S, Nagahama M, et al. Vitamin-D receptor genotype and renal disorder in Japanese patients with systemic lupus erythematosus. Nephron. 2000 May;85(1):86–91.

69. Huang CM, Wu MC, Wu JY, Tsai FJ. Association of vitamin D receptor gene Bsml polymorphisms in Chinese patients with systemic lupus erythematosus. Lupus. 2002;11(1):31–4.

70. Holick MF, Binkley NC, et al. Evaluation, treatment, and prevention of vitamin d deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jul;96(7):1911–30. doi: 10.1210/jc.2011-0385. Epub 2011 Jun 6.

71. Institute of Medicine. Institute of Medicine dietary reference intakes for calcium and vitamin D. Washington, DC: The National Academics Press; 2011.

72. Rossini M, Bongi SM, La Montagna G, et al. Vitamin D deficiency in rheumatoid arthritis: prevalence, determinants and associations with disease activity and disability. Arthritis Res Ther. 2010;12(6):R216. doi: 10.1186/ar3195. Epub 2010 Nov 29.

73. Bischoff-Ferrari HA, Giovannucci E, Willett WC, et al. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr. 2006 Jul;84(1):18–28.

74. Abe J, Nakamura K, Takita Y, et al. Prevention of immunological disorders in MRL/l mice by a new synthetic analogue of vitamin D3: 22-oxa-1 alpha, 25-dihydroxyvitamin D3. J Nutr Sci Vitaminol (Tokyo). 1990 Feb;36(1):21–31.

75. Shoenfeld N, Amital H, Shoenfeld Y. The effect of melanism amd vitamin D synthesis on the incidence of autoimmune disease. Nat Clin Pract Rheumatol. 2009 Feb;5(2):99–105. doi: 10.1038/ncprheum0989.

76. Adorini L. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol. 2005 Feb;233(2):115–24.

77. Lemire JM, Ince A, Takashima M. 1,25-Dihydroxyvitamin D3 attenuates the expression of experimental murine lupus of MRL/l mice. Autoimmunity. 1992;12(2):143–8.

78. Koizumi T, Nakao Y, Matsui T, et al. Effects of corticosteroid and 1,25-dihydroxyvitamin D3 administration on lymphoproliferation and autoimmune disease in MRL/MPlpr/ lpr mice. Int Arch Allergy Appl Immunol. 1985;77(4):396–404.

79. Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence. Proc Soc Exp Biol Med. 2000 Mar;223(3):230–3.

80. van Etten E, Branisteanu DD, Verstuyf A, et al. Analogs of 1,25-dihydroxyvitamin D3 as dose-reducing agents for classical immunosupressants. Transplantation. 2000 May 15;69(9):1932–42.

81. Abou-Raya A, Abou-Raya S, Helmii M. The effect of vitamin D supplementation on inflammatory and hemostatic markers and disease activity in patients with systemic lupus erythematosus: a randomized placebo-controlled trial. J Rheumatol. 2013 Mar;40(3):265–72. doi: 10.3899/jrheum.111594. Epub 2012 Dec 1.

82. Petri M, Bello KJ, Fang H, Magder LS. Vitamin D in systemic lupus erythematosus: modest association with disease activity and the urine protein-to-creatinine ratio. Arthritis Rheum. 2013 Jul;65(7):1865–71. doi: 10.1002/art.37953.

83. Adami S, Giannini S, Bianchi C, et al. Vitamin D status and response to treatment in post-menopausal osteoporosis. Osteoporos Int. 2009 Feb;20(2):239–44. doi: 10.1007/ s00198-008-0650-y. Epub 2008 Jun 13.

84. Geller JL, Hu B, Reed S, et al. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients. Endocr Pract. 2008 Apr;14(3):293–7.

85. Yeap SS, Othman AZ, Zain AA, Chan SP. Vitamin D levels: its relationship to bone mineral density response and disease activity in premenopausal Malaysian systemic lupus erythematosus patients on corticosteroids. Int J Rheum Dis. 2012 Feb;15(1):17–24. doi: 10.1111/j.1756-185X.2011.01653.x. Epub 2011 Aug 31.

86. Ishijima M, Sakamoto Y, Yamanaka M, et al. Minimum required vitamin D level for optimal increase in bone mineral density with alendronate treatment in osteoporotic women. Calcif Tissue Int. 2009 Nov;85(5):398–404. doi: 10.1007/s00223- 009-9295-x. Epub 2009 Oct 1.

87. Dawson-Hughes B, Chen P, Krege JH. Response to teriparatide in patients with baseline 5-hydroxyvitamin D insufficiency or sufficiency. J Clin Endocrinol Metab. 2007 Dec;92(12):4630–6. Epub 2007 Oct 2.

88. Antoniucci DM, Vittinghoff E, Blackwell T, et al. Vitamin D insufficiency does not affect bone mineral density response o taloxifene. J Clin Endocrinol Metab. 2005 Aug;90(8):4566–72. Epub 2005 May 17.

89. Ruiz-Irastorza G, Egurbide MV, Olivares N, et al. Vitamin D deficiency in systemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatology (Oxford). 2008 Jun;47(6):920–3. doi: 10.1093/rheumatology/ken121. Epub 2008 Apr 14.

90. Cusack C, Danby C, Fallon JC, et al. Photoprotective behaviour and sunscreen use: impact on vitamin D levels in cutaneous lupus erythematosus. Photodermatol Photoimmunol Photomed. 2008 Oct;24(5):260–7. doi: 10.1111/j.1600- 0781.2008.00373.x.

91. Cutillas-Marco E, Morales-Suaœrez-Varela M, Marquina-Vila A, Grant W. Serum 25-hydroxyvitamin D levels in patients with cutaneous lupus erythematosus in a Mediterranean region. Lupus. 2010 Jun;19(7):810–4. doi: 10.1177/09612033 09360807. Epub 2010 Mar 19.

92. M’Barek RB, Dupre T, Tubach F, et al. 25-hydroxyvitamin D status dos not affect the clinical rituximab response in rheumatoid arthritis. Joint Bone Spine. 2014 Jan;81(1):96–7. doi: 10.1016/j.jbspin.2013.04.017. Epub 2013 Jun 21.


Для цитирования:


Клюквина Н.Г. Системная красная волчанка и в и тамин D. Современная ревматология. 2015;9(2):57-65. https://doi.org/10.14412/1996-7012-2015-2-57-65

For citation:


Klyukvina N.G. Systemic lupus erythematosus and vitamin D. Modern Rheumatology Journal. 2015;9(2):57-65. (In Russ.) https://doi.org/10.14412/1996-7012-2015-2-57-65

Просмотров: 537


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)